3 Auto Components Maker, Branded Pharmaceuticals Company and Engines and Power Systems Maker Stocks With a Strong Future Roadmap: Sandhar Technologies, Eris Lifesciences and Cummins India

Auto locks, branded pharma and engine stocks give investors a way to track businesses that sit close to everyday demand in India. Sandhar Technologies, Eris Lifesciences and Cummins India cover an auto components maker, a branded pharmaceuticals company and an engines and power systems maker.

This list covers three auto locks, branded pharma and engine stocks with complete current figures: Sandhar Technologies, Eris Lifesciences and Cummins India. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Auto Locks, Branded Pharma and Engine Stocks?

Auto locks, branded pharma and engine stocks are listed companies that make locks, mirrors, wheels and safety parts for vehicles, develop and sell branded medicines for lifestyle and chronic conditions, and build engines, generators and power systems. Their earnings depend on vehicle output, prescription demand and industrial and data centre investment.

Auto Locks, Branded Pharma and Engine Stocks at a Glance

On valuation, Sandhar Technologies and Eris Lifesciences trade at a P/E below the industry P/E, while Cummins India trades above it, which reflects the growth the market already expects. Readers comparing auto locks, branded pharma and engine stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in auto locks, branded pharma and engine stocks can use the coming numbers to test whether growth is holding.

Why Do Auto Locks, Branded Pharma and Engine Stocks Have a Strong Roadmap in India?

Auto locks, branded pharma and engine stocks have a strong roadmap in India because rising vehicle production, growing lifestyle disease care and heavy investment in power backup and industry keep widening the market for these companies.

• Auto components. Vehicles need many safety and comfort parts.
• Branded pharma. Chronic care demand keeps rising.
• Engines and gensets. Factories and data centres need reliable power.

Why Sandhar Technologies Features Among These Auto Locks, Branded Pharma and Engine Stocks

Among the auto locks, branded pharma and engine stocks on this list, Sandhar Technologies supplies safety systems, locks, mirrors, wheels, aluminium die castings and sheet metal parts to two-wheeler, commercial vehicle and passenger vehicle makers.

The company has a return on equity of 14.9%, a debt to equity ratio of 0.86 and a market capitalisation of Rs 3,135 crore. The stock trades at a P/E of 15.1, below the industry P/E of 36.9.

Revenue rose from Rs 2,331 crore in FY22 to Rs 4,927 crore in FY26, a compound annual growth rate of 20.6%. Net profit grew from Rs 55.9 crore in FY22 to Rs 199 crore in FY26, which works out to a compound annual growth rate of 37.3%. In the June 2026 quarter, revenue grew 25.6% year on year to Rs 1,394 crore, while net profit rose 33.1% to Rs 37.3 crore.

Roadmap: The company supplies leading vehicle makers and has been growing its content per vehicle through new product lines. It has also expanded in aluminium die casting and in electronics and mechatronics.

What to watch: Watch new product ramp-ups and growth in the electric two-wheeler segment.

Why Eris Lifesciences Features Among These Auto Locks, Branded Pharma and Engine Stocks

Among the vehicle safety part, chronic medicine and genset shares on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.

Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%.

In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.

Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.

Why Cummins India Features Among These Auto Locks, Branded Pharma and Engine Stocks

Among the three companies on this list, Cummins India makes diesel and natural gas engines, generator sets, filtration products and power systems for infrastructure, data centres and industrial customers, and it also exports.

In the June 2026 quarter, revenue grew 17.2% year on year to Rs 3,563 crore, while net profit rose 0.9% to Rs 609 crore. Revenue rose from Rs 6,414 crore in FY22 to Rs 12,661 crore in FY26, a compound annual growth rate of 18.5%.

Net profit grew from Rs 934 crore in FY22 to Rs 2,362 crore in FY26, which works out to a compound annual growth rate of 26.1%. The company has a return on equity of 27.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 127,515 crore. The stock trades at a P/E of 53.9, above the industry P/E of 44.4.

Roadmap: The company benefits from demand for backup power at data centres, infrastructure projects and industrial plants, and it is widening its export base. A debt-free balance sheet supports capacity additions and new product lines.

What to watch: Track demand from data centres and new infrastructure and the growth of exports.

Sandhar Technologies vs Eris Lifesciences vs Cummins India on Key Financials

The table below sets the three auto locks, branded pharma and engine stocks side by side on revenue, profit and margin, using reported figures.

Cummins India posts the highest return on equity in this group at 27.9%. Cummins India has the largest FY26 revenue at Rs 12,661 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with auto locks, branded pharma and engine stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several mirror and lock maker, diabetes drug and power engine stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Auto Locks, Branded Pharma and Engine Stocks

Every theme carries risks that deserve a check before any decision. For these auto locks, branded pharma and engine stocks, the main points are: Long-term vehicle safety part, chronic medicine and genset shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Production cycles. Vehicle output can vary with demand.
• Pricing pressure. Generic prices can change by market.
• Capital spending cycles. Customer investment in plants and equipment can vary.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter auto locks, branded pharma and engine stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Auto Locks, Branded Pharma and Engine Stocks

Auto locks, branded pharma and engine stocks work best when investors track growth, valuation and return on equity side by side. Sandhar Technologies, Eris Lifesciences and Cummins India each have a clear plan to grow. Based on the 11 November 2026 close, Sandhar Technologies trades at Rs 503.3, Eris Lifesciences at Rs 1,275.1 and Cummins India at Rs 4,229.8. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these auto locks, branded pharma and engine stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track auto locks, branded pharma and engine stocks, set price alerts and get research-backed stock ideas.

What are auto locks, branded pharma and engine stocks?

Ans. Auto locks, branded pharma and engine stocks are listed companies that make locks, mirrors, wheels and safety parts for vehicles, develop and sell branded medicines for lifestyle and chronic conditions, and build engines, generators and power systems. Their earnings depend on vehicle output, prescription demand and industrial and data centre investment. This list looks at three of them, Sandhar Technologies, Eris Lifesciences and Cummins India, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which auto locks, branded pharma and engine stocks are covered in this list?

Ans. This list covers Sandhar Technologies, Eris Lifesciences and Cummins India. Based on the 11 November 2026 close, Sandhar Technologies traded at Rs 503.3, Eris Lifesciences at Rs 1,275.1 and Cummins India at Rs 4,229.8. Their return on equity ranges from 14.9% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 18.5% to 22.9%.

Why do auto locks, branded pharma and engine stocks have a strong future roadmap in India?

Ans. Auto locks, branded pharma and engine stocks have a strong roadmap in India because rising vehicle production, growing lifestyle disease care and heavy investment in power backup and industry keep widening the market for these companies. The main drivers are as follows. Auto components. Vehicles need many safety and comfort parts. Branded pharma. Chronic care demand keeps rising. Engines and gensets. Factories and data centres need reliable power. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Sandhar Technologies performed financially?

Ans. Revenue rose from Rs 2,331 crore in FY22 to Rs 4,927 crore in FY26, a compound annual growth rate of 20.6%. Net profit grew from Rs 55.9 crore in FY22 to Rs 199 crore in FY26, which works out to a compound annual growth rate of 37.3%. In the June 2026 quarter, revenue grew 25.6% year on year to Rs 1,394 crore, while net profit rose 33.1% to Rs 37.3 crore. The company has a return on equity of 14.9%, a debt to equity ratio of 0.86 and a market capitalisation of Rs 3,135 crore. The stock trades at a P/E of 15.1, below the industry P/E of 36.9. Looking ahead, the company supplies leading vehicle makers and has been growing its content per vehicle through new product lines. It has also expanded in aluminium die casting and in electronics and mechatronics.

How has Eris Lifesciences performed financially?

Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

How has Cummins India performed financially?

Ans. Revenue rose from Rs 6,414 crore in FY22 to Rs 12,661 crore in FY26, a compound annual growth rate of 18.5%. Net profit grew from Rs 934 crore in FY22 to Rs 2,362 crore in FY26, which works out to a compound annual growth rate of 26.1%. In the June 2026 quarter, revenue grew 17.2% year on year to Rs 3,563 crore, while net profit rose 0.9% to Rs 609 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 127,515 crore. The stock trades at a P/E of 53.9, above the industry P/E of 44.4. Looking ahead, the company benefits from demand for backup power at data centres, infrastructure projects and industrial plants, and it is widening its export base. A debt-free balance sheet supports capacity additions and new product lines.

What risks should investors check before buying auto locks, branded pharma and engine stocks?

Ans. Investors should check a few risks before buying auto locks, branded pharma and engine stocks. Production cycles. Vehicle output can vary with demand. Pricing pressure. Generic prices can change by market. Capital spending cycles. Customer investment in plants and equipment can vary. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of auto locks, branded pharma and engine stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.